The Benefit of More Cells

More cells overall

While many parents are banking their babies' cord blood, you can do more by banking stem cells from 2 usable sources of stem cell-rich blood: the umbilical cord and the placenta. This service is called Placenta-Cord banking, and it's available only from LifebankUSA^®.

Banking placental blood in addition to cord blood doubles the number of segments preserved and increases the total number of stem cells available.¹ This is important for 2 reasons. First, transplanting more stem cells has been shown to increase the probability of transplant success and survival.^2-4 Second, having multiple segments available may offer the potential to treat additional conditions that may affect your baby and/or other close family members (blood relatives).^5-7

More CD34+ stem cells

Compared to cord blood banking alone, Placenta-Cord banking yields 39% more of a particular type of cell called a CD34+ stem cell.¹ Studies have shown that using more CD34+ stem cells can lead to a significant survival advantage in transplant patients.^4-7

Effect of CD34+ Cells

Data from: Wagner JE, Barker JN, DeFor TE, et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood. 2002;100(5):1611-1618.

These findings are from a study of 102 patients at the University of Minnesota School of Medicine and Cancer Center

More mesenchymal-like stem cells

Someday, having more cells available may prove beneficial for new treatments in an emerging medical field called regenerative medicine. This medical approach involves repairing or replacing damaged tissues and organs and restoring their critical structure and function.*^8,9

Studies now show that stem cells referred to as mesenchymal^✝ cells may prove useful for regenerative treatments.^10-13 Placental and cord blood contain mesenchymal-like cells, including CD105+200+ cells.^{‡ 1,14} With Placenta-Cord banking, you can ensure that more of these mesenchymal-like cells are saved so that your family can take advantage of new treatments that may emerge.

More CD34+ cells. More mesenchymal-like cells. More cells overall. When it comes to lifesaving potential, only LifebankUSA gives you MORE.

*These uses are not consistent with current labeling, are investigational and may never become standard therapy.
^✝ Mesenchymal is pronounced muh-ZINK-i-mul.
^‡Data on file, LifebankUSA; 2010.

"As a family with a history of heart disease, type 1 diabetes, and Parkinson's disease, we have to face the possibility that we may someday need treatment involving stem cells. If that day ever comes, I will want to know that we have done everything possible to prepare for a successful procedure. We've chosen Placenta-Cord banking with LifebankUSA because we understand that having more cells could make a lifesaving difference when the moment arrives."

-Christine S.
LifebankUSA client,
New Jersey

*These uses are not consistent with current labeling, are investigational and may never become standard therapy.

THOUGHTS ON REGENERATIVE MEDICINE
"Stem cells are a mainstay of regenerative medicine. These cells are the 'blank slates' of the body-they haven't committed to becoming a skin cell, heart cell or kidney cell..Stem cells cannot only be coaxed down a certain life path (to become a heart muscle cell, for example, or a liver cell), they also can latch on to tissue in the body and become that type of tissue."

-Alliance for Aging Research
http://agingresearch.org/content/article/detail/911

Cord blood and placenta-derived stem cells banked with LifebankUSA are indicated for hematopoietic reconstitution (the reformation of blood cellular components) for autologous use or use in first or second degree blood relatives. Any use of cord blood and placental stem cells other than for hematopoietic reconstitution is considered investigational, including regenerative medicine* therapies.

The chance that a child will use his/her own stored stem cells during his/her lifetime for currently treated conditions is estimated at 1 in 400 (J.J. Nietfeld). These odds may increase if there is a family history of certain blood disorders or cancers. The potential risks and benefits of stem cell transplantation vary and depend on many factors, such as the amount and quality of the stem cells collected, the HLA compatibility between recipient and donor, and the client’s overall health. Talk with your health care provider. For more information, call us at 1-877-LIFEBANKUSA (1-877-543-3226) or visit www.lifebankusa.com. View Product Information.

*These uses are not consistent with current labeling, are investigational and may never become standard therapy.

References:

Data on file A, LifebankUSA; 2010.
Gluckman E, Rocha V. Donor selection for unrelated cord blood transplants. Curr Opin Immunol. 2006;18(5):565-570.
Schoemans H, Theunissen K, Maertens J, Boogaerts M, Verfaillie C, Wagner J. Adult umbilical cord blood transplantation: a comprehensive review. Bone Marrow Transplant. 2006:38(2):83-93.
Scaradavou A, on behalf of the National Cord Blood Program. Unrelated umbilical cord blood unit selection. Semin Hematol.47:13-21.
Wagner JE, Barker JN, DeFor TE, et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood. 2002;100(5):1611-1618.
Cairo MS, Wagner EL, Fraser J, et al. Characterization of banked umbilical cord blood hematopoietic progenitor cells and lymphocyte subsets and correlation with ethnicity, birth weight, sex, and type of delivery: a Cord Blood Transplantation (COBLT) Study report. Transfusion. 2005;45(6):856-866.
Styczynski J, Cheung Y-K, Garvin J, et al. Unrelated donor transplants: outcomes of unrelated cord blood transplantation in pediatric recipients. Bone Marrow Transplant. 2004;34(2):129-136.
Mason C, Dunnill P. A brief definition of regenerative medicine. Regen Med. 2008;3(1):1-5.
US Department of Health and Human Services. 2020: a new vision-a future for regenerative medicine. http://www.hhs.gov/reference/newfuture.shtml. Accessed April 14, 2010.
Harris DT. Non-haematological uses of cord blood stem cells. Br J Haematol. 2009;147(2):177-184.
Richardson SM, Hoyland JA, Mobasheri R, Csaki C, Shakibaei M, Mobasheri A. Mesenchymal stem cells in regenerative medicine: opportunities and challenges for articular cartilage and intervertebral disc tissue engineering. J Cell Physiol. 2010;222(1):23-32.
Yen BL, Huang H-I, Chien C-C, et al. Isolation of multipotent cells from human term placenta. Stem Cells. 2005;23(1):3-9.
da Silva Meirelles L, Caplan AI, Nardi NB. In search of the in vivo identity of mesenchymal stem cells. Stem Cells. 2008;26(9):2287-2299.
Nietfeld JJ, Pasquini MC, Logan BR, Verter F, Horowitz MM. Lifetime probabilities of hematopoietic stem cell transplantation in the U.S. Biol Blood Marrow Transplant. 2008;14(3):316-322.